STOCK TITAN

Fortress Biotech CEO buys 137K shares in November

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Fortress Biotech, Inc. (FBIO) President, CEO and Chairman Lindsay A. Md Rosenwald reported purchases totaling 136,723 shares across November 17–19, 2026. The weighted average prices were $1.7973 for 64,491 shares on November 17, $1.9029 for 54,776 shares on November 18, and $1.8584 for 17,456 shares on November 19. No Rule 10b5-1 plan is reported.

Insider ROSENWALD LINDSAY A MD
Role PRESIDENT, CEO & CHAIRMAN
Bought 136,723 shs ($253K)
Type Security Shares Price Value
Purchase Common Stock, par value $0.001 F1 17,456 $1.8584 $32K
Purchase Common Stock, par value $0.001 F1 54,776 $1.9029 $104K
Purchase Common Stock, par value $0.001 F1 64,491 $1.7973 $116K
Holdings After Transaction: Common Stock, par value $0.001 — 4,723,564 shares (Direct)
Footnotes (1)
  1. F1. The prices reported in Column 4 are weighted average prices. The shares were purchased in multiple transactions in prices ranging from $1.685 to $1.85 on November 17, 2026, $1.87 to $1.97 on November 18, 2026, and $1.81 to $1.895 on November 19, 2026, in each case inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this note.
Shares purchased 64,491 shares November 17, 2026
Weighted average purchase price $1.7973 per share November 17, 2026
Shares purchased 54,776 shares November 18, 2026
Weighted average purchase price $1.9029 per share November 18, 2026
Shares purchased 17,456 shares November 19, 2026
Weighted average purchase price $1.8584 per share November 19, 2026
weighted average prices financial
"Column 4 are weighted average prices"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FBIO shares did Lindsay A. Md Rosenwald buy?

Lindsay A. Md Rosenwald, Fortress Biotech’s President, CEO and Chairman, reported purchases totaling 136,723 shares: 64,491 on November 17, 54,776 on November 18, and 17,456 on November 19, 2026. No Rule 10b5-1 plan is reported.

What prices did Lindsay A. Md Rosenwald pay for FBIO shares?

The weighted average purchase prices were $1.7973, $1.9029, and $1.8584 per share on November 17, 18, and 19, 2026, respectively. The reported prices across multiple transactions ranged from $1.685 to $1.85, $1.87 to $1.97, and $1.81 to $1.895 on those dates, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROSENWALD LINDSAY A MD

(Last)(First)(Middle)
C/O FORTRESS BIOTECH, INC.
1111 KANE CONCOURSE SUITE 301

(Street)
BAY HARBOR ISLANDS FLORIDA 33154

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Fortress Biotech, Inc. [ FBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT, CEO & CHAIRMAN
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.00111/17/2026P64,491A$1.7973(1)4,651,332D
Common Stock, par value $0.00111/18/2026P54,776A$1.9029(1)4,706,108D
Common Stock, par value $0.00111/19/2026P17,456A$1.8584(1)4,723,564D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The prices reported in Column 4 are weighted average prices. The shares were purchased in multiple transactions in prices ranging from $1.685 to $1.85 on November 17, 2026, $1.87 to $1.97 on November 18, 2026, and $1.81 to $1.895 on November 19, 2026, in each case inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this note.
/s/ David Jin, Attorney-in-Fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading